- Home
- HPP vs AVTX Comparison
HPP vs AVTX Comparison
Compare HPP & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPP | AVTX |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.3M | 801.8M |
| IPO Year | 2010 | 2015 |
Fundamental Metrics
Financial Performance| Metric | HPP | AVTX |
|---|---|---|
| Price | $11.88 | $13.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $16.82 | ★ $44.08 |
| AVG Volume (30 Days) | 583.4K | ★ 986.0K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $831,105,000.00 | $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $1.67 | $12.51 |
| 52 Week High | $17.20 | $24.27 |
Technical Indicators
Market Signals| Indicator | HPP | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 26.89 |
| Support Level | $11.02 | $12.98 |
| Resistance Level | $12.36 | $20.54 |
| Average True Range (ATR) | 0.51 | 0.88 |
| MACD | 0.09 | -0.17 |
| Stochastic Oscillator | 62.68 | 15.16 |
Price Performance
Historical ComparisonAbout HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a vertically integrated real estate investment trust offering end-to-end real estate solutions for dynamic tenants in the synergistic, converging and secular growth industries of tech and media. It acquires, repositions, develops and operates sustainable high-quality office studio properties in high-barrier-to-entry tech and media epicenters. Its primary investment markets include Los Angeles, the San Francisco Bay Area, Seattle, New York and Vancouver, British Columbia. Its segments include Office properties and related operations and Studio properties and related operations. The majority of the revenue is derived from Office properties and related operations segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.